# Biotech Daily Digest ‚Äî 2025-10-15

**47 items from 6 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 8 items
- Fierce Biotech: 7 items
- MHRA ‚Äì News: 2 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 28 items


## Eli Lilly Press Releases

- **[Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-superior-glycemic)**  
  _Wed, 15 Oct 2025 06:45:00 -0400_  
  In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with ¬† dapagliflozin, meeting the primary endpoint In ACHIEVE-5,¬†orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint INDIANAPOLIS , Oct.


## Endpoints News

- **[Boehringer makes an ADC deal with AimedBio; EyePoint‚Äôs $150M stock sale](https://endpoints.news/boehringer-makes-an-adc-deal-with-aimedbio-eyepoints-150m-stock-sale/)**  
  _Wed, 15 Oct 2025 14:38:15 +0000_  
  Plus, news about Scynexis, Step Pharma, Eradivir, J&J, Omnix Medical and Mission Therapeutics:

 üíº Boehringer Ingelheim does another cancer deal: The German drugmaker will pay up to $991 million to Seoul ...

- **[Which big pharma had the busiest M&A team? Q3 biopharma deal analysis](https://endpoints.news/which-big-pharma-had-the-busiest-ma-team-q3-biopharma-deal-analysis/)**  
  _Wed, 15 Oct 2025 11:00:20 +0000_  
  Biotech execs generally point to need as the biggest driver of dealmaking. Some of the biggest players ‚Äî say Merck and Bristol Myers Squibb ‚Äî are losing major franchises and have a limited time to fill the ...

- **[Mark Pruzanski joins Alentis as CEO after leading Intercept and Versanis](https://endpoints.news/mark-pruzanski-joins-alentis-as-ceo-after-leading-intercept-and-versanis/)**  
  _Wed, 15 Oct 2025 11:00:15 +0000_  
  Mark Pruzanski has found another fibrosis drug developer to lead, and this time he's also venturing into oncology.

 The biotech industry veteran has joined Swiss startup Alentis Therapeutics as its new CEO, the company exclusively ...

- **[Hair loss biotech Pelage collects $120M for Phase 3 trials](https://endpoints.news/hair-loss-biotech-pelage-collects-120m-for-phase-3-trials/)**  
  _Wed, 15 Oct 2025 11:00:14 +0000_  
  In the span of three weeks, a seven-employee biotech focused on hair loss raised $120 million for Phase 3 trials that will begin next year.

 Los Angeles-based Pelage Pharmaceuticals announced the Series B on Wednesday ...

- **[Tubulis snags $361M for clinical-stage ADCs](https://endpoints.news/tubulis-snags-361m-for-clinical-stage-adcs/)**  
  _Wed, 15 Oct 2025 09:00:17 +0000_  
  Tubulis is headed to one of the leading cancer R&D conferences with the fifth-largest private biotech fundraise of 2025.

 The Munich-based ADC biotech will present its first clinical data at the European Society for Medical ...

- **[Reinventing mental healthcare in the age of AI](https://endpoints.news/reinventing-mental-healthcare-in-the-age-of-ai/)**  
  _Tue, 14 Oct 2025 19:21:11 +0000_  
  Headspace CEO Tom Pickett has been on the job for a little more than a year now. His focus during that time has been guiding the company through the ‚Äútechnology transition‚Äù brought on by generative ...

- **[Pfizer claims first-line success for Tukysa in breast cancer Phase 3 trial](https://endpoints.news/pfizer-claims-first-line-success-for-tukysa-in-breast-cancer-phase-3-trial/)**  
  _Tue, 14 Oct 2025 18:22:10 +0000_  
  Pfizer‚Äôs Tukysa succeeded as a first-line maintenance therapy in combination with other standard-of-care drugs for certain metastatic breast cancer patients, the company said Tuesday.

 In a Phase 3 trial, the TKI inhibitor was given in ...

- **[J&J CEO downplays any need for 'large' acquisition as it gears up for new launches](https://endpoints.news/jj-ceo-downplays-any-need-for-large-acquisition-as-it-gears-up-for-new-launches/)**  
  _Tue, 14 Oct 2025 17:41:05 +0000_  
  As Johnson & Johnson faces increasing pressure from Stelara generics, the company's executives remain confident in their pipeline‚Äôs ability to fill in the gaps.

 On Tuesday‚Äôs third-quarter earnings call, CEO Joaquin Duato and CFO Joseph ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/boehringer-ingelheim-digs-adcs-offering-nearly-1b-license-cancer-prospect-koreas-aimedbio" hreflang="en">Boehringer Ingelheim digs in on ADCs, offering up to $991M to license cancer prospect from Korea's AimedBio</a>](https://www.fiercebiotech.com/biotech/boehringer-ingelheim-digs-adcs-offering-nearly-1b-license-cancer-prospect-koreas-aimedbio)**  
  _Oct 15, 2025 9:42am_  
  Boehringer Ingelheim will pay AimedBio up to $991 million to license and develop one of the South Korean biotech‚Äôs antibody-drug conjugates across a ‚Äúbroad range of cancers." The ADC asset girding the deal targets a protein expressed in many malignancies that plays a ‚Äúsignificant role‚Äù in tumor growth, metastasis and‚Ä¶

- **[<a href="https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins" hreflang="en">Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins</a>](https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins)**  
  _Oct 15, 2025 9:16am_  
  Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca‚Äôs Farxiga to stay on track to seek approval in the indication next year.

- **[<a href="https://www.fiercebiotech.com/biotech/tubulis-nets-361m-financing-round-next-gen-adc-data-drop-nears" hreflang="en">Tubulis nets $361M financing as next-gen ADC data drop nears</a>](https://www.fiercebiotech.com/biotech/tubulis-nets-361m-financing-round-next-gen-adc-data-drop-nears)**  
  _Oct 13, 2025 3:23pm_  
  Germany's Tubulis has closed a $361 million series C financing round with help from new investors Venrock Healthcare Capital Partners, Wellington Management and Ascenta Capital. The cash will help expand clinical development of Tubulis‚Äô lead asset, TUB-040, and expand the company's bespoke antibody drug conjugate plat‚Ä¶

- **[<a href="https://www.fiercebiotech.com/medtech/boehringer-click-release-trial-results-digital-app-treat-negative-symptoms-schizophrenia" hreflang="en">Boehringer, Click‚Äôs digital therapeutic meets phase 3 goal in schizophrenia</a>](https://www.fiercebiotech.com/medtech/boehringer-click-release-trial-results-digital-app-treat-negative-symptoms-schizophrenia)**  
  _Oct 14, 2025 12:12pm_  
  German drugmaker Boehringer Ingelheim and Click Therapeutics said their phase 3 trial of a prescription digital therapeutic for the negative symptoms of schizophrenia met its primary endpoint.

- **[<a href="https://www.fiercebiotech.com/biotech/lila-sciences-adds-115m-series-bringing-total-haul-350m-and-securing-backing-nvidia" hreflang="en">Lila Sciences adds Nvidia-backed $115M to series A, bringing total haul to $350M</a>](https://www.fiercebiotech.com/biotech/lila-sciences-adds-115m-series-bringing-total-haul-350m-and-securing-backing-nvidia)**  
  _Oct 14, 2025 11:15am_  
  Flagship Pioneering‚Äôs Lila Sciences has had little trouble finding supporters for its ‚Äúscientific superintelligence‚Äù mission since its March debut. After closing a $235 million series A last month, Lila has now expanded the round with an additional $115 million, including funds from the venture arm of AI titan Nvidia.

- **[<a href="https://www.fiercebiotech.com/medtech/jj-spinning-orthopedics-unit-all-about-shrinking-grow-faster" hreflang="en">J&amp;J move to spin off orthopedics unit is 'all about shrinking to grow faster,' exec says</a>](https://www.fiercebiotech.com/medtech/jj-spinning-orthopedics-unit-all-about-shrinking-grow-faster)**  
  _Oct 14, 2025 11:14am_  
  Two years after spinning off its $15 billion consumer health unit as Kenvue, Johnson & Johnson is slimming down again, unveiling a plan to separate from its orthopedics business, transforming it into a standalone company.

- **[<a href="https://www.fiercebiotech.com/medtech/roche-nabs-fda-clearance-alzheimers-biomarker-blood-test" hreflang="en">Roche nabs FDA clearance for Alzheimer‚Äôs biomarker blood test</a>](https://www.fiercebiotech.com/medtech/roche-nabs-fda-clearance-alzheimers-biomarker-blood-test)**  
  _Oct 14, 2025 11:14am_  
  Roche, which currently has investigational Alzheimer‚Äôs disease drug trontinemab in phase 3 trials, secured FDA clearance for its blood-based biomarker test for the condition.


## MHRA ‚Äì News

- **[The new Innovative Licensing and Access Pathway welcomes first investigational products](https://www.gov.uk/government/news/the-new-innovative-licensing-and-access-pathway-welcomes-first-investigational-products)**  
  _2025-10-14T23:01:01Z_  
  Developers work with the NHS, the medicines regulator and the UK health technology assessment bodies from the early stages of clinical development, as part of the Innovative Licensing and Access Pathway.

- **[100 years of protecting patients through biological standards for medicines](https://www.gov.uk/government/news/100-years-of-protecting-patients-through-biological-standards-for-medicines)**  
  _2025-10-14T17:24:37Z_  
  The MHRA produces over 95 per cent of the World Health Organization‚Äôs (WHO) biological standards.


## Regeneron Press Releases

- **[Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers](https://investor.regeneron.com/news-releases/news-release-details/regeneron-showcases-advances-across-oncology-portfolio-and)**  
  _Wed, 15 Oct 2025 07:00:00 -0400_  
  New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo¬Æ (cemiplimab) in high-risk cutaneous squamous cell carcinoma TARRYTOWN, N.Y. , Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.


## arXiv q-bio

- **[scPPDM: A Diffusion Model for Single-Cell Drug-Response Prediction](https://arxiv.org/abs/2510.11726)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11726v1 Announce Type: new 
Abstract: This paper introduces the Single-Cell Perturbation Prediction Diffusion Model (scPPDM), the first diffusion-based framework for single-cell drug-response prediction from scRNA-seq data. scPPDM couples two condition channels, pre-perturbation state and drug with dose, in‚Ä¶

- **[PRISM: Enhancing Protein Inverse Folding through Fine-Grained Retrieval on Structure-Sequence Multimodal Representations](https://arxiv.org/abs/2510.11750)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11750v1 Announce Type: new 
Abstract: Designing protein sequences that fold into a target three-dimensional structure, known as the inverse folding problem, is central to protein engineering but remains challenging due to the vast sequence space and the importance of local structural constraints. Existing d‚Ä¶

- **[Optimal Pair Matching Combined with Machine Learning Predicts a Significant Reduction in Myocardial Infarction Risk in African Americans following Omega-3 Fatty Acid Supplementation](https://arxiv.org/abs/2510.11756)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11756v1 Announce Type: new 
Abstract: Conflicting clinical trial results on omega-3 highly unsaturated fatty acids (n-3 HUFA) have prompted uncertainty about their cardioprotective effects. While the VITAL trial found no overall cardiovascular benefit from n-3 HUFA supplementation, its substantial African A‚Ä¶

- **[Inpainting the Neural Picture: Inferring Unrecorded Brain Area Dynamics from Multi-Animal Datasets](https://arxiv.org/abs/2510.11924)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11924v1 Announce Type: new 
Abstract: Characterizing interactions between brain areas is a fundamental goal of systems neuroscience. While such analyses are possible when areas are recorded simultaneously, it is rare to observe all combinations of areas of interest within a single animal or recording sessio‚Ä¶

- **[Genomic Influence of a Key Transcription Factor in Male Glandular Malignancy](https://arxiv.org/abs/2510.11959)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11959v1 Announce Type: new 
Abstract: Prostate cancer (PCa) remains a significant global health concern among men, particularly due to the lethality of its more aggressive variants. Despite therapeutic advancements that have enhanced survival for many patients, high grade PCa continues to contribute substan‚Ä¶

- **[An Efficient Algorithm for Exploring RNA Branching Conformations under the Nearest-Neighbor Thermodynamic Model](https://arxiv.org/abs/2510.12059)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12059v1 Announce Type: new 
Abstract: Background: In the Nearest-Neighbor Thermodynamic Model, a standard approach for RNA secondary structure prediction, the energy of the multiloops is modeled using a linear entropic penalty governed by three branching parameters. Although these parameters are typically f‚Ä¶

- **[MAPS: Masked Attribution-based Probing of Strategies- A computational framework to align human and model explanations](https://arxiv.org/abs/2510.12141)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12141v1 Announce Type: new 
Abstract: Human core object recognition depends on the selective use of visual information, but the strategies guiding these choices are difficult to measure directly. We present MAPS (Masked Attribution-based Probing of Strategies), a behaviorally validated computational tool th‚Ä¶

- **[Readout Representation: Redefining Neural Codes by Input Recovery](https://arxiv.org/abs/2510.12228)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12228v1 Announce Type: new 
Abstract: Sensory representation is typically understood through a hierarchical-causal framework where progressively abstract features are extracted sequentially. However, this causal view fails to explain misrepresentation, a phenomenon better handled by an informational view ba‚Ä¶

- **[Phenome-Wide Multi-Omics Integration Uncovers Distinct Archetypes of Human Aging](https://arxiv.org/abs/2510.12384)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12384v1 Announce Type: new 
Abstract: Aging is a highly complex and heterogeneous process that progresses at different rates across individuals, making biological age (BA) a more accurate indicator of physiological decline than chronological age. While previous studies have built aging clocks using single-o‚Ä¶

- **[ECMSim: A high-performance web simulation of cardiac ECM remodeling through integrated ODE-based signaling and diffusion](https://arxiv.org/abs/2510.12577)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12577v1 Announce Type: new 
Abstract: Extracellular matrix (ECM) remodeling is central to a wide variety of healthy and diseased tissue processes. Unfortunately, predicting ECM remodeling under various chemical and mechanical conditions has proven to be excessively challenging, due in part to its complex re‚Ä¶

- **[Recent Advances in Microfluidics and Bioelectronics for Three-Dimensional Organoid Interfaces](https://arxiv.org/abs/2510.12584)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12584v1 Announce Type: new 
Abstract: Organoids offer a promising alternative in biomedical research and clinical medicine, with better feature recapitulation than 2D cultures. They also have more consistent responses with clinical results when compared to animal models. However, major challenges exist in t‚Ä¶

- **[Same model, better performance: the impact of shuffling on DNA Language Models benchmarking](https://arxiv.org/abs/2510.12617)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12617v1 Announce Type: new 
Abstract: Large Language Models are increasingly popular in genomics due to their potential to decode complex biological sequences. Hence, researchers require a standardized benchmark to evaluate DNA Language Models (DNA LMs) capabilities. However, evaluating DNA LMs is a complex‚Ä¶

- **[Non-linear associations of amyloid-$\beta$ with resting-state functional networks and their cognitive relevance in a large community-based cohort of cognitively normal older adults](https://arxiv.org/abs/2510.12751)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12751v1 Announce Type: new 
Abstract: Background: Non-linear alterations in brain network connectivity may represent early neural signatures of Alzheimer's disease (AD) pathology in cognitively normal older adults. Understanding these changes and their cognitive relevance could provide sensitive biomarkers‚Ä¶

- **[TopROI: A topology-informed network approach for tissue partitioning](https://arxiv.org/abs/2510.12772)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12772v1 Announce Type: new 
Abstract: Mammalian tissue architecture is central to biological function, and its disruption is a hallmark of disease. Medical imaging techniques can generate large point cloud datasets that capture changes in the cellular composition of such tissues with disease progression. Ho‚Ä¶

- **[A Quantum Generative Framework for Modeling Single-Cell Transcriptomes with Gene-Gene and Cell-Cell Interactions](https://arxiv.org/abs/2510.12776)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12776v1 Announce Type: new 
Abstract: Single-cell RNA sequencing (scRNA-seq) data simulation is limited by classical methods that rely on linear correlations, failing to capture the intrinsic, nonlinear dependencies and the simultaneous gene-gene and cell-cell interactions. We introduce qSimCells, a novel h‚Ä¶

- **[Inhomogeneous continuous-time Markov chains to infer flexible time-varying evolutionary rates](https://arxiv.org/abs/2510.11982)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.11982v1 Announce Type: cross 
Abstract: Reconstructing evolutionary histories and estimating the rate of evolution from molecular sequence data is of central importance in evolutionary biology and infectious disease research. We introduce a flexible Bayesian phylogenetic inference framework that accommodate‚Ä¶

- **[Modeling Epidemics on Multiplex Networks: Epidemic Threshold and Basic Reproduction Number](https://arxiv.org/abs/2510.12614)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12614v1 Announce Type: cross 
Abstract: Accurate epidemic forecasting requires models that account for the layered and heterogeneous nature of real social interactions. The basic reproduction number $\mathcal R_0$ calculated from models that assume homogeneous mixing or single-layer contact structures have‚Ä¶

- **[Multitask finetuning and acceleration of chemical pretrained models for small molecule drug property prediction](https://arxiv.org/abs/2510.12719)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12719v1 Announce Type: cross 
Abstract: Chemical pretrained models, sometimes referred to as foundation models, are receiving considerable interest for drug discovery applications. The general chemical knowledge extracted from self-supervised training has the potential to improve predictions for critical dr‚Ä¶

- **[Disentangling Neurodegeneration with Brain Age Gap Prediction Models: A Graph Signal Processing Perspective](https://arxiv.org/abs/2510.12763)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.12763v1 Announce Type: cross 
Abstract: Neurodegeneration, characterized by the progressive loss of neuronal structure or function, is commonly assessed in clinical practice through reductions in cortical thickness or brain volume, as visualized by structural MRI. While informative, these conventional appro‚Ä¶

- **[An "adaptive" approach to control explosive aphid populations](https://arxiv.org/abs/2310.03058)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2310.03058v2 Announce Type: replace 
Abstract: Classical models of aphid population dynamics are unable to explain multi-peak patterns in field populations. We consider the variable carrying capacity model (VCM), which can generate such complex multi-peak dynamics, but is also demonstrated to show finite-time bl‚Ä¶

- **[The spatially variable effects of mangroves on flood depths and losses from storm surges in Florida](https://arxiv.org/abs/2506.09078)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2506.09078v3 Announce Type: replace 
Abstract: Mangroves modify storm surges with impacts on property damages, but these effects vary spatially and by storm intensity. We use high-resolution, kilometer-scale flood and loss models to examine variability in mangrove effects on surge losses to properties, spatially‚Ä¶

- **[HelixVS: Deep Learning-Enhanced Structure-Based Platform for Screening and Design](https://arxiv.org/abs/2508.10262)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2508.10262v2 Announce Type: replace 
Abstract: Drug discovery through virtual screening (VS) has become a popular strategy for identifying hits against protein targets. Alongside VS, molecular design further expands accessible chemical space. Together, these approaches have the potential to reduce the cost and t‚Ä¶

- **[Algorithmic Implementation: An Introduction to a Low-Cost, GUI-Based, Semi-Unsupervised Microscopy Segmentation Framework](https://arxiv.org/abs/2509.11354)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2509.11354v2 Announce Type: replace 
Abstract: This article presents a novel microscopy image analysis framework designed for low-budget labs equipped with a standard CPU desktop. The Python-based program enables cytometric analysis of live, unstained cells in culture through an advanced computer vision and mach‚Ä¶

- **[A Hybrid ABM-PDE Framework for Real-World Infectious Disease Simulations](https://arxiv.org/abs/2504.08430)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2504.08430v2 Announce Type: replace-cross 
Abstract: This paper presents a hybrid modeling approach that couples an Agent-Based Model (ABM) with a partial differential equation (PDE) model in an epidemic setting to simulate the spatial spread of infectious diseases using a compartmental structure with seven heal‚Ä¶

- **[Open and Sustainable AI: challenges, opportunities and the road ahead in the life sciences (October 2025 -- Version 2)](https://arxiv.org/abs/2505.16619)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2505.16619v2 Announce Type: replace-cross 
Abstract: Artificial intelligence (AI) has recently seen transformative breakthroughs in the life sciences, expanding possibilities for researchers to interpret biological information at an unprecedented capacity, with novel applications and advances being made almost d‚Ä¶

- **[Protein Design with Dynamic Protein Vocabulary](https://arxiv.org/abs/2505.18966)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2505.18966v2 Announce Type: replace-cross 
Abstract: Protein design is a fundamental challenge in biotechnology, aiming to design novel sequences with specific functions within the vast space of possible proteins. Recent advances in deep generative models have enabled function-based protein design from textual d‚Ä¶

- **[Riemannian generative decoder](https://arxiv.org/abs/2506.19133)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2506.19133v2 Announce Type: replace-cross 
Abstract: Riemannian representation learning typically relies on an encoder to estimate densities on chosen manifolds. This involves optimizing numerically brittle objectives, potentially harming model training and quality. To completely circumvent this issue, we introd‚Ä¶

- **[The Algorithmic Regulator](https://arxiv.org/abs/2510.10300)**  
  _Wed, 15 Oct 2025 00:00:00 -0400_  
  arXiv:2510.10300v2 Announce Type: replace-cross 
Abstract: The regulator theorem states that, under certain conditions, any optimal controller must embody a model of the system it regulates, grounding the idea that controllers embed, explicitly or implicitly, internal models of the controlled. This principle underpins‚Ä¶
